Latest:
Dr. Bouvet Discusses Risk Factors for Thyroid Cancer
Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses risk factors for thyroid cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Michael Brawer, MD
Latest:
Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer
Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Michael Cookson, MD
Latest:
Dr. Cookson on Understanding Predictive Features in the Management of Prostate Cancer
Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.
Michael D. Mix, MD
Latest:
Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLC
Michael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).
Michael Folkert, MD, PhD
Latest:
Stereotactic Radiation Potential Emerges in Prostate Cancer
Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.
Michael Gnant, MD
Latest:
Dr. Michael Gnant on the PAM50 Breast Cancer Intrinsic Subtypes
Michael Gnant, MD, professor of the Department of Surgery at the Medical University of Vienna in Vienna, Austria, discusses the four intrinsic subtypes of the PAM50 recurrence score test and a clinical trial comparing this test with OncotypeDX.